February 12, 2015
ARLINGTON, Va. — HDMA President and CEO John M. Gray released a statement in support of the Ensuring Patient Access and Effective Drug Enforcement Act of 2015, introduced today by Senators Orrin Hatch (R-Utah) and Sheldon Whitehouse (D-R.I.) The legislation is a companion to House legislation (H.R. 471) sponsored by Reps. Tom Marino (R-Pa.), Marsha Blackburn (R-Tenn.), Peter Welch (D-Vt.) and Judy Chu (D-Calif.)
“A strong, collaborative relationship between the nation’s pharmaceutical supply chain and enforcement agencies ― such as the Drug Enforcement Administration ― is critical to the ability of our country to help mitigate prescription drug abuse and diversion. The bipartisan legislation introduced by Senators Hatch and Whitehouse is an important step forward in achieving this goal, by promoting transparency in the fight against abuse and diversion. It is HDMA’s hope and expectation that this Senate bill will have the same broad support and momentum that the House legislation currently enjoys.”
HDA is the national association representing primary healthcare distributors, the vital link between the nation’s pharmaceutical manufacturers and healthcare providers. Each business day, HDA member companies ensure that over 15 million prescription medicines and healthcare products are delivered safely and efficiently to more than 200,000 pharmacies, hospitals, long-term care facilities, clinics and others nationwide. HDA and its members work daily to provide value and achieve cost savings, an estimated $42 billion each year to our nation’s healthcare system.